Skip to main
OPRX
OPRX logo

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx Corp demonstrated a robust financial performance, with contracted revenue increasing by 30% year-over-year and significant revenue outperformance that positively impacted margins and earnings per share. The company's guidance for 2025 indicates improved revenue visibility, with over 85% visibility on total revenue and an EBITDA forecast above consensus, suggesting strong financial health and operational stability. Additionally, as digital interactions between pharmaceutical companies and healthcare providers continue to rise, OptimizeRx is well-positioned to capture market share and achieve revenue growth in the high teens to low twenties, while effectively managing operating costs.

Bears say

OptimizeRx Corp operates in a competitive healthcare digital messaging sector but currently faces challenges in revenue growth, which has been inconsistent over recent quarters. The company’s reliance on a limited number of pharmaceutical partnerships for a substantial portion of its revenue creates vulnerability, particularly in a shifting market landscape. Additionally, rising operational costs and further investments required for technology enhancements may pressure profit margins, fueling concerns over the sustainability of its financial performance.

OptimizeRx Corp (OPRX) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 7 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of Nov 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.